Table 6

Cox proportional hazards model for MACCE at 12 months

UnivariateMultivariate: model 1Multivariate: model 2
HR95% CIP valueHR95% CIP valueHR95% CIP value
DAPT at discharge0.64(0.29 to 1.42)0.2720.41(0.15 to 1.13)0.0860.41(0.15 to 1.13)0.086
Cilostazol at discharge0.58(0.22 to 1.54)0.2740.48(0.16 to 1.46)0.1980.48(0.16 to 1.46)0.198
Warfarin at discharge1.13(0.39 to 3.30)0.8210.89(0.28 to 2.88)0.8510.89(0.28 to 2.88)0.851
Male0.93(0.39 to 2.22)0.8671.29(0.48 to 3.51)0.6151.29(0.48 to 3.51)0.615
Prior lower limb revascularisation1.55(0.71 to 3.39)0.2751.80(0.79 to 4.13)0.1631.8(0.79 to 4.13)0.163
Prior coronary revascularisation1.32(0.58 to 2.99)0.5061.37(0.56 to 3.36)0.4871.37(0.56 to 3.36)0.487
  • Model 1: adjusted for DAPT at discharge, cilostazol at discharge, warfarin at discharge, male, prior lower limb revascularisation and prior coronary revascularisation.

  • Model 2: shared-frailty model with each institution and ID as a random intercept, adjusted for variable in model 1.

  • DAPT, dual antiplatelet therapy; MACCE, major adverse cardiovascular and cerebrovascular event.